The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Celgene Corp

Nasdaq: CELG
Last

(U.S.) $119.16

Today's change-1.71 -1.41%
Updated January 30 4:00 PM EST. Delayed by at least 15 minutes.
 

Celgene Corp

Nasdaq: CELG
Last

(U.S.) $119.16

Today's change-1.71 -1.41%
Updated January 30 4:00 PM EST. Delayed by at least 15 minutes.

Celgene Corp down (U.S.)$1.71

Celgene Corp closed lower Friday, dropping (U.S.)$1.71 or 1.41% to (U.S.)$119.16. Shares have lost 3.82% over the last five days, but sit 4.37% below their 52-week high. This security has outperformed the S&P 500 by 43.58% during the last year.

Key company metrics

  • Open(U.S.) $119.49
  • Previous close(U.S.) $120.87
  • High(U.S.) $124.29
  • Low(U.S.) $118.89
  • Bid / Ask-- / --
  • YTD % change+6.53%
  • Volume8,129,114
  • Average volume (10-day)4,849,880
  • Average volume (1-month)5,435,078
  • Average volume (3-month)5,174,750
  • 52-week range(U.S.) $66.85 to (U.S.) $124.60
  • Beta1.08
  • Trailing P/E49.72×
  • P/E 1 year forward24.58×
  • Forward PEG0.95×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.40
Updated January 30 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+26.07%

Based on its net profit margin of 26.07%, Celgene Corp is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.25%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue2,0861,9821,8731,730
Total other revenue--------
Total revenue2,0861,9821,8731,730
Gross profit1,9821,8851,7741,644
Total cost of revenue103989986
Total operating expense1,3341,3381,1161,368
Selling / general / administrative544498492494
Research & development585675457714
Depreciation / amortization64646566
Interest expense (income), net operating--------
Unusual expense (income)38439
Other operating expenses, total--------
Operating income752645757362
Interest income (expense), net non-operating-52-64-52-40
Gain (loss) on sale of assets--------
Other--------
Income before tax711578707332
Income after tax614509598280
Income tax, total976910953
Net income614509598280
Total adjustments to net income--------
Net income before extra. items614509598280
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items614509598280
Inc. avail. to common incl. extra. items614509598280
Diluted net income614509598280
Dilution adjustment--------
Diluted weighted average shares835833831845
Diluted EPS excluding extraordinary itemsvalue per share0.740.610.720.33
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.770.610.720.34